Compare ZVRA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVRA | SANA |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.9M | 1.4B |
| IPO Year | 2015 | 2021 |
| Metric | ZVRA | SANA |
|---|---|---|
| Price | $8.25 | $5.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $21.71 | $7.83 |
| AVG Volume (30 Days) | 1.2M | ★ 5.2M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $84,388,000.00 | N/A |
| Revenue This Year | $333.25 | N/A |
| Revenue Next Year | $43.70 | N/A |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | ★ 244.60 | N/A |
| 52 Week Low | $6.19 | $1.26 |
| 52 Week High | $13.16 | $7.30 |
| Indicator | ZVRA | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 62.87 |
| Support Level | $8.24 | $4.25 |
| Resistance Level | $9.03 | $5.43 |
| Average True Range (ATR) | 0.35 | 0.50 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 15.93 | 91.65 |
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.